OEC signs fluoroscope deal with Genzyme:
This article was originally published in Clinica
Executive Summary
Genzyme of Cambridge, Massachusetts, and OEC Medical Systems of Salt Lake City, Utah, have reached an agreement for OEC to supply its Series 9600 cardiac mobile fluoroscope systems to Genzyme's cardiovascular units. At the same time the companies will now co-market their respective technologies in minimally-invasive cardiovascular surgery, through combined sales and training materials.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.